This research seeks to develop antibody-based reagents that will block SARS-CoV-2 entry into cells while avoiding worsening clinical outcomes in immune-compromised patients, such as cancer patients. Unlike many other approaches to developing antibodies, this particular strategy is unique in that it recognizes and avoids the potential hazards associated with conventional antibody strategy, specifically antibody dependent enhancement (ADE), and complement activation, both of which have the potential to exacerbate rather than improve COVID-19, particularly in immunocompromised populations.